

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



北京市春立正達醫療器械股份有限公司  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 1858)**

## **ANNOUNCEMENT ON ESTIMATED RESULTS FOR THE YEAR 2025**

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

### **I. ESTIMATED RESULTS FOR THE PERIOD**

#### **1. Period of the estimated results**

1 January 2025 to 31 December 2025.

#### **2. Estimated results**

- (i) Based on the preliminary estimate of the financial department of the Company, it is estimated that the net profit attributable to owners of the parent company for the year of 2025 will range from RMB244,988,000 to RMB287,988,000, which is increased by RMB120,000,000 to RMB163,000,000 (or increased by 96.01% to 130.41%) as compared to the same period last year.
- (ii) It is estimated that the net profit attributable to owners of the parent company after deducting non-recurring profit or loss will range from RMB229,536,000 to RMB269,536,000, which is increased by RMB135,000,000 to RMB175,000,000 (or increased by 142.80% to 185.11%) as compared to the same period last year.

3. The estimated results have not been audited by a certified public accountant. The Company has conducted preliminary discussions with the accounting firm responsible for auditing its annual report on matters related to the estimated results, and there is no material disagreement between the Company and the accounting firm in relation to the estimated results.

## **II. RESULTS AND FINANCIAL POSITION FOR THE SAME PERIOD LAST YEAR**

1. The total profit for the same period last year amounted to RMB131,599,200, the net profit attributable to owners of the parent company amounted to RMB124,988,000, and the net profit attributable to owners of the parent company after deducting non-recurring profit or loss amounted to RMB94,536,000.
2. The earnings per share for the same period last year amounted to RMB0.33.

## **III. THE MAIN REASONS FOR THE CHANGE IN RESULTS FOR THE CURRENT PERIOD**

In 2025, both the net profit attributable to shareholders of the Company and the net profit after deducting non-recurring profit or loss achieved significant growth compared with the same period last year. During the reporting period, the product lines of the Company gradually unleashed their growth potential after being included in centralized procurement. Simultaneously, the Company continued to implement its internationalization development strategy and steadily advancing its international business footprint. By leveraging both domestic and international efforts, the Company achieved sustained, stable, and healthy growth in operating revenue. Moreover, the Company's commitment to improving operational management and optimizing resource allocation further enhanced operating efficiency and bolstered overall profitability, providing strong foundational support for its performance growth.

## **IV. RISK WARNING**

The estimated results for the year 2025 represent preliminary estimates prepared by the finance department of the Company in accordance with the Accounting Standards for Business Enterprises and have not been audited by a certified public accountant. As of the date of this announcement, the Company has not identified any material uncertainties in the Company that may affect the accuracy of the estimated results.

## V. OTHER EXPLANATORY MATTERS

The foregoing estimated data is a preliminary estimation only. Detailed and accurate financial data of the Company to be disclosed in the 2025 annual report of the Company shall prevail.

**Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
*Chairman*  
**Shi Wenling**

Beijing, the PRC, 29 January 2026

*As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Weng Jie and Mr. Wong Tak Shing.*

*\* For identification purposes only*